Literature DB >> 28410272

Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.

Pierre Albaladejo1, Charles-Marc Samama, Pierre Sié, Sophie Kauffmann, Vincent Mémier, Pierre Suchon, Alain Viallon, Jean Stéphane David, Yves Gruel, Lorenn Bellamy, Emmanuel de Maistre, Pauline Romegoux, Sophie Thoret, Gilles Pernod, Jean-Luc Bosson.   

Abstract

BACKGROUND: The use of prothrombin complex concentrates and the role of plasma concentration of anticoagulants in the management of bleeding in patients treated with direct oral anticoagulants are still debated. Our aim was to describe management strategies and outcomes of severe bleeding events in patients treated with direct oral anticoagulants.
METHODS: We performed a prospective cohort study of 732 patients treated with dabigatran, rivaroxaban, or apixaban hospitalized for severe bleeding, included prospectively in the registry from June 2013 to November 2015.
RESULTS: Bleeding was gastrointestinal or intracranial in 37% (212 of 732) and 24% (141 of 732) of the cases, respectively. Creatinine clearance was lower than 60 ml/min in 61% (449 of 732) of the cases. The plasma concentration of direct oral anticoagulants was determined in 62% (452 of 732) of the cases and was lower than 50 ng/ml or higher than 400 ng/ml in 9.2% (41 of 452) and in 6.6% (30 of 452) of the cases, respectively. Activated or nonactivated prothrombin complex concentrates were administered in 38% of the cases (281 of 732). Mortality by day 30 was 14% (95% CI, 11 to 16).
CONCLUSIONS: Management of severe bleeding in patients treated with direct oral anticoagulants appears to be complex. The use of prothrombin complex concentrates differs depending on bleeding sites and direct oral anticoagulant plasma concentrations. Mortality differs according to bleeding sites and was similar to previous estimates.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28410272     DOI: 10.1097/ALN.0000000000001631

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  10 in total

Review 1.  The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

Authors:  Maureane Hoffman; Joshua N Goldstein; Jerrold H Levy
Journal:  Int J Emerg Med       Date:  2018-12-03

2.  The reversal of anticoagulation in clinical practice .

Authors:  Sally Thomas; Michael Makris
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

Review 3.  Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis.

Authors:  Siavash Piran; Rasha Khatib; Sam Schulman; Ammar Majeed; Anne Holbrook; Daniel M Witt; Wojtek Wiercioch; Holger J Schünemann; Robby Nieuwlaat
Journal:  Blood Adv       Date:  2019-01-22

4.  Severe Hemorrhage Associated With Oral Anticoagulants.

Authors:  Edelgard Lindhoff-Last; Eva Herrmann; Simone Lindau; Stavros Konstantinides; Oliver Grottke; Ulrike Nowak-Goettl; Jessica Lucks; Barbara Zydek; Christian von Heymann; Ingvild Birschmann; Ariane Sümnig; Jan Beyer-Westendorf; Sebastian Schellong; Patrick Meybohm; Andreas Greinacher
Journal:  Dtsch Arztebl Int       Date:  2020-05-01       Impact factor: 5.594

5.  A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding.

Authors:  Tessa Jaspers; Kimberly Shudofsky; Menno V Huisman; Karina Meijer; Nakisa Khorsand
Journal:  Res Pract Thromb Haemost       Date:  2021-05-24

6.  Clinical and endoscopic features of severe acute gastrointestinal bleeding in elderly patients treated with direct oral anticoagulants: a multicentre study.

Authors:  David Deutsch; Pauline Romegoux; Christian Boustière; Jean-Marc Sabaté; Robert Benamouzig; Pierre Albaladejo
Journal:  Therap Adv Gastroenterol       Date:  2019-06-17       Impact factor: 4.409

7.  The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis.

Authors:  Sariya Udayachalerm; Sasivimol Rattanasiri; Teeranan Angkananard; John Attia; Nakarin Sansanayudh; Ammarin Thakkinstian
Journal:  Clin Appl Thromb Hemost       Date:  2018-09-03       Impact factor: 2.389

8.  Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.

Authors:  Anne-Laure Sennesael; Anne-Sophie Larock; Jonathan Douxfils; Laure Elens; Gabriel Stillemans; Martin Wiesen; Max Taubert; Jean-Michel Dogné; Anne Spinewine; François Mullier
Journal:  Thromb J       Date:  2018-11-12

9.  Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry.

Authors:  Edelgard Lindhoff-Last; Ingvild Birschmann; Joachim Kuhn; Simone Lindau; Stavros Konstantinides; Oliver Grottke; Ulrike Nowak-Göttl; Jessica Lucks; Barbara Zydek; Christian von Heymann; Ariane Sümnig; Jan Beyer-Westendorf; Sebastian Schellong; Patrick Meybohm; Andreas Greinacher; Eva Herrmann
Journal:  Thromb Haemost       Date:  2021-09-29       Impact factor: 6.681

Review 10.  An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.

Authors:  Mark Terence P Mujer; Manoj P Rai; Varunsiri Atti; Ian Limuel Dimaandal; Abigail S Chan; Shiva Shrotriya; Krishna Gundabolu; Prajwal Dhakal
Journal:  Adv Hematol       Date:  2020-01-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.